Physician profile
John B Clemmons
NPI 1518997477
$8,789.89
in general payments reported to CMS, 2019-2025
32 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $744 · 2021: $1,718 · 2022: $1,272 · 2023: $1,581 · 2024: $1,226 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,109 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,108.77 |
| Education | $123.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,330.20 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,476.13 | 2019-2025 | Mavyret, Linzess, Viberzi |
| Janssen Biotech, INC. | $828.07 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $800.51 | 2019-2023 | |
| Pfizer INC. | $554.82 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $347.11 | 2019-2024 | Eohilia, Entyvio, Gattex |
| Evoke Pharma, INC. | $185.35 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $150.55 | 2020-2024 | Rebyota |
| Redhill Biopharma INC. | $141.41 | 2020-2023 | Talicia |
| Mallinckrodt Hospital Products INC. | $130.00 | 2025 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $125.60 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $91.65 | 2019-2025 | General - Biliary Devices |
| Nestle Healthcare Nutrition INC. | $87.29 | 2021-2022 | |
| Novo Nordisk INC | $79.36 | 2021-2025 | Ozempic |
| Vivus LLC | $53.76 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $40.00 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $38.00 | 2019-2021 | |
| Celgene Corporation | $35.11 | 2021 | |
| Ardelyx, INC. | $31.28 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $30.54 | 2024 | Mounjaro |
| Glaxosmithkline, LLC. | $29.56 | 2020-2021 | |
| Allergan, INC. | $26.62 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $26.00 | 2024 | Bylvay |
| Amgen INC. | $24.91 | 2019 | |
| Ironwood Pharmaceuticals, INC | $22.24 | 2023 | Linzess |
| Braintree Laboratories, INC. | $21.27 | 2023 | Sutab |
| Napo Pharmaceuticals INC | $19.36 | 2024 | Mytesi |
| Conmed Corporation | $17.46 | 2023 | Conmed Dilation |
| Horizon Therapeutics Plc | $16.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.08 | 2019 | |
| Olympus America INC. | $11.85 | 2019 | |
| Qol Medical, LLC | $4.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Clemmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.